Feb 28, 2005 by Charly TraversAnother Drug Sector ShockerPatient death triggers voluntary withdrawal of MS drug Tysabri.
Feb 25, 2005 by Charly TraversProtein Design Labs' FutureA look ahead to a transitional year -- and how much ESP acquisition will boost revenues -- coming Monday.
Feb 24, 2005 by Charly TraversTranskaryotic's TurnaroundSuperb management creating shareholder value.
Feb 23, 2005 by Charly TraversQLT Is Still a ValueThe market's concerns mean this company is being offered up at a great price.
Feb 18, 2005 by Charly TraversA Drug to Get Your Blood PumpingEncysive's Thelin combines low risk with high sales potential.
Feb 10, 2005 by Charly TraversFocus on the PipelineVertex Pharmaceuticals is losing money. But it has at least one drug that makes the future look brighter.
Feb 8, 2005 by Charly TraversInvesting in a CureDrugs in the pipeline offer potential breakthroughs for Alzheimer's disease.
Feb 8, 2005 by Charly TraversGood Prognosis for Biogen IDECBlockbuster products help the biotech firm continue its stellar performance.
Jan 26, 2005 by Charly TraversCall Cubist in the MorningStrong drug sales provide a dose of good medicine for this pharmaceutical company.
Jan 25, 2005 by Charly TraversGrading Old-School BiotechBe very wary of biotech IPOs from companies lacking drugs.
Jan 21, 2005 by Charly TraversSeeing the Value in QLTA narrow-minded market could be creating a great drug value.
Jan 18, 2005 by Charly TraversBiotech Class of 2004Hot drugs are leading to smokin' stock performances.
Jan 11, 2005 by Charly TraversThe Future of Cancer VaccinesCan a vaccine help stave off forms of the disease?
Jan 4, 2005 by Charly TraversCloning FluffyIs the pet cloning industry fertile ground for finding Rule Breakers?
Dec 30, 2004 by Charly TraversGenzyme Enters Cancer ArenaThe approval of a new drug is a long-term opportunity.
Dec 28, 2004 by Charly TraversIt's All in the DeliveryIf too much risk makes you queasy, these drug companies are for you.
Dec 21, 2004 by Charly TraversInvest With Fewer Side EffectsAverse to risk? Check out these nontraditional drug companies.
